USPTO Ruling Impacts Editas Medicine CRISPR IP Position

Editas Medicine ( (EDIT) ) has issued an update.

Editas Medicine, Inc. is a biotechnology company focused on developing gene-editing therapies based on CRISPR/Cas9 technology. It operates in the genomic medicine industry, aiming to translate gene-editing innovations into treatments for human diseases, and its competitive position is closely tied to the intellectual property landscape around CRISPR technologies.

The company announced that on March 26, 2026, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s prior decision in favor of the Broad Institute in a key U.S. patent interference over CRISPR/Cas9 editing in human cells. This outcome, following a partial affirmance and vacatur by the Federal Circuit in May 2025, helps solidify the Broad’s IP position in CRISPR/Cas9 for human cells, a development that may influence Editas Medicine’s access to foundational CRISPR technology, while the opposing CVC parties retain the right to appeal.

The most recent analyst rating on (EDIT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.

Spark’s Take on EDIT Stock

According to Spark, TipRanks’ AI Analyst, EDIT is a Neutral.

The score is held down primarily by weak financial performance (revenue collapse to $0, persistent losses, and heavy negative free cash flow) despite relatively low debt and some cost containment. Technicals are a notable offset, with the stock trading above major moving averages and positive MACD, but valuation remains constrained by unprofitability (negative P/E) and no dividend support.

To see Spark’s full report on EDIT stock, click here.

More about Editas Medicine

Editas Medicine, Inc. is a biotechnology company focused on developing gene-editing therapies based on CRISPR/Cas9 technology. It operates in the genomic medicine industry, aiming to translate gene-editing innovations into treatments for human diseases, and its competitive position is closely tied to the intellectual property landscape around CRISPR technologies.

The company announced that on March 26, 2026, the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s prior decision in favor of the Broad Institute in a key U.S. patent interference over CRISPR/Cas9 editing in human cells. This outcome, following a partial affirmance and vacatur by the Federal Circuit in May 2025, helps solidify the Broad’s IP position in CRISPR/Cas9 for human cells, a development that may influence Editas Medicine’s access to foundational CRISPR technology, while the opposing CVC parties retain the right to appeal.

Average Trading Volume: 1,777,297

Technical Sentiment Signal: Sell

Current Market Cap: $227.1M

For detailed information about EDIT stock, go to TipRanks’ Stock Analysis page.